Zhaoke Ophthalmology Ltd. (HK:6622) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Zhaoke Ophthalmology Ltd. announced the approval of its Investigational New Drug application for Cyclosporine A Ophthalmic Gel by China’s NMPA, targeting treatment for dry eye disease, and also completed a pivotal Phase III trial for NVK002, aimed at controlling myopia in children. The company highlights the potential improvement in patient compliance and quality of life with its innovative treatments. With a burgeoning market for dry eye disease treatments in China and a focus on myopia prevention in the nation’s health plan, Zhaoke’s developments are positioned in a rapidly expanding healthcare segment.
For further insights into HK:6622 stock, check out TipRanks’ Stock Analysis page.